Dianthus Therapeutics Overview
Dianthus Therapeutics Target Price
Analysts' 12-month price predictions for DNTH.
Get informed when a big investor buys or sells
+ FollowShare Price
$87.37
Average Target Price
$118.91
36.1% upside
36.1% upside11 analysts in the last 4 months
High: $145 | Low: $98
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-06-10 | Jefferies | $132 | 51.1% upside |  |
| 2026-05-11 | Evercore ISIGavin Clark-Gartner | $120 | 37.3% upside | |
| 2026-05-06 | Raymond James | $125 | 43.1% upside | |
| 2026-04-08 | Wolfe ResearchAndy Chen | $98 | 12.2% upside | |
| 2026-03-09 | UBSMaury Raycroft | $98 | 12.2% upside | |
| 2026-03-09 | JefferiesMaury Raycroft | $98 | 12.2% upside | |
| 2026-03-09 | Robert W. Baird | $132 | 51.1% upside | |
| 2026-03-09 | H.C. WainwrightSwayampakula Ramakanth | $130 | 48.8% upside | |
| 2026-03-09 | OppenheimerTrevor Allred | $145 | 66% upside | |
| 2026-03-09 | Stifel NicolausAlex Thompson | $120 | 37.3% upside | |
| 2026-03-09 | Truist Financial | $110 | 25.9% upside | |
| 2026-02-11 | Wedbush | $55 |  37% downside | |
| 2026-01-29 | UBS | $125 | 43.1% upside | |
| 2026-01-08 | Truist Financial | $63 | 27.9% downside | |
| 2025-11-06 | OppenheimerTrevor Allred | $62 | 29% downside | |
| 2025-10-14 | Truist FinancialDanielle Brill | $56 | 35.9% downside | |
| 2025-09-08 | GuggenheimYatin Suneja | $100 | 14.5% upside | |
| 2025-09-08 | JefferiesMaury Raycroft | $51 | 41.6% downside | |
| 2024-11-11 | OppenheimerLeland Gershell | $52 | 40.5% downside | |
| 2024-04-18 | Raymond JamesSteven Seedhouse | $51 | 41.6% downside | |